Previous close | 0.0940 |
Open | 0.0960 |
Bid | 0.0890 x 53590500 |
Ask | 0.0940 x 50748300 |
Day's range | 0.0890 - 0.0960 |
52-week range | 0.0890 - 0.2050 |
Volume | |
Avg. volume | 1,410,200 |
Market cap | 158.231M |
Beta (5Y monthly) | 3.07 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0130 |
Earnings date | 22 Aug 2022 - 28 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 0.32 |
ImpediMed Limited (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health is pleased to announce a poster showing strong correlation between ImpediMed's SOZO® Digital Health Platform and dual x-ray absorptiometry (DXA) for assessing bone mineral content in cancer patients was presented at the 39th Annual Miami Breast Cancer Conference on 3-6 March 2022 in Miami Beach, Florida, USA.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
ImpediMed Limited (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health is pleased to announce an abstract comparing concurrent measures using ImpediMed's SOZO® Digital Health Platform and dual x-ray absorptiometry (DXA) for assessing bone mineral content in cancer patients was accepted for poster presentation at the 39th Annual Miami Breast Cancer Conference on 3-6 March 2022 in Miami Beach, Florida, USA